---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-063523"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T18:46:55.375001+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion Q1 loss $29.3M; realigns on diabetes/obesity, cuts workforce 35%

## Summary
- Q1 net loss $29.3M ($36.2M cash); cash runway extended into Q4 2025.
- Strategic realignment: 35% workforce reduction; focus on icovamenib and oral GLP-1 BMF-650.
- R&D expenses $22.9M (down from $33.8M YoY); G&A $6.8M (down from $7.3M).
- Phase II COVALENT-111 52-week T2D data expected H2 2025; Type-C meeting with FDA planned.
- Interim CEO Mick Hitchcock appointed March 2025; oncology BMF-500 partnership exploration.

## SEC filing metadata
- accession: 0000950170-25-063523
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000095017025063523/0000950170-25-063523-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000095017025063523/bmea-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-063523
- JSON: https://secwatch.observer/filing/0000950170-25-063523.json
- Plain text: https://secwatch.observer/filing/0000950170-25-063523.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.